Professor Jérôme Frenette is a researcher with a background in physical therapy and post-graduate training in muscle physiology and immunology at the University of California in Los-Angeles. He is a full-time researcher at the Centre de recherche du CHU de Québec-Laval University, and full professor in the department of rehabilitation at Laval University’s School of Medicine. He has been the principal investigator on several CIHR and NSERC grants. Many of his publications, and one CIHR grant were recognized and rewarded as being among the best in the field of muscle physiology. He started his career as a researcher by investigating the roles played by blood cells and mechanical loading in models of tendon injury and muscle atrophy/regrowth. In 2005, he expanded his research program to include the Buruli Ulcer, which is caused by mycobacterium ulcerans, a neglected disease of wet tropical zones, that is closely related to tuberculosis and leprosy. His research group was the first to show that mycobacterium ulcerans and its toxin, mycolactone, extend well beyond the skin, and severely affect underlying skeletal muscles. Today, the focus of his research program is to understand the link between osteoporosis and muscle atrophy/disease through one common pathway i.e. the RANK/RANKL/OPG pathway. In collaboration with Duchenne muscular dystrophy foundations in Canada, the United States and Australia, as well as sustainable financial support from public and private sources, his team is developing new drugs that would potentially alleviate, in tandem, osteoporosis and muscle degeneration in Duchenne muscular dystrophy patients or other forms of bone and muscle diseases.
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2
- Argaw, AntenehEmployeeCHUL+1 418-525-4444, extension 48840Anteneh.Argaw@crchudequebec.ulaval.ca
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2 - Bouredji, ZinebEmployeeCHUL+1 418-525-4444, extension 47954zineb.bouredji.1@ulaval.cazineb.bouredji@crchudequebec.ulaval.ca
2705, boul. Laurier
P-09800
Québec, Québec
Canada G1V 4G2 - Facchin, AnthonyDoctoral studentCHUL+1 418-525-4444, extension 47954anthony.facchin.1@crchudequebec.ulaval.caanthony.facchin.1@ulaval.ca
2705, boulevard Laurier
P-09800
Québec, QC
Canada G1V 4G2
Dystrophin expression following the transplantation of normal muscle precursor cells protects mdx muscle from contraction-induced damage
Journal ArticleCell Transplant, 19 (5), 2010.
Thrombocytopenia alters early but not late repair in a mouse model of Achilles tendon injury
Journal ArticleWound Repair Regen, 17 (2), 2009.
Limited repair and structural damages displayed by skeletal muscles loaded with mycolactone
Journal ArticleMicrobes Infect, 11 (2), 2009.
Neutrophil-induced skeletal muscle damage: a calculated and controlled response following hindlimb unloading and reloading
Journal ArticleAm J Physiol Regul Integr Comp Physiol, 295 (6), 2008.
Subcutaneous injection of Mycobacterium ulcerans causes necrosis, chronic inflammatory response and fibrosis in skeletal muscle
Journal ArticleMicrobes Infect, 10 (12-13), 2008.
Mast cells can modulate leukocyte accumulation and skeletal muscle function following hindlimb unloading
Journal ArticleJ Appl Physiol (1985), 103 (1), 2007.
Inflammatory cells do not decrease the ultimate tensile strength of intact tendons in vivo and in vitro: protective role of mechanical loading
Journal ArticleJ Appl Physiol (1985), 102 (1), 2007.
Pifithrin-alpha, an inhibitor of p53 transactivation, alters the inflammatory process and delays tendon healing following acute injury
Journal ArticleAm J Physiol Regul Integr Comp Physiol, 292 (1), 2007.
Early voluntary exercise does not promote healing in a rat model of Achilles tendon injury
Journal ArticleJ Appl Physiol (1985), 101 (6), 2006.
Periodic direct current does not promote wound closure in an in vitro dynamic model of cell migration
Journal ArticlePhys Ther, 86 (1), 2006.
Active projects
- Decipher the physiological functions of osteoprotegerin in skeletal and cardiac muscles, from 2023-04-01 to 2028-03-31
- Multifunctional properties of osteoprotegerin in muscular dystrophy and muscle repair, from 2020-04-01 to 2025-03-31
Recently finished projects
- Development of a glycobiology therapy to mitigate the progression of Duchenne muscular dystrophy, from 2021-07-01 to 2023-02-28
- Development of a monosaccharide therapy using N-acetylglucosamine to mitigate Duchenne muscular dystrophy, from 2021-05-31 to 2024-05-30
- Investigation of the role of galectin-3 and its ligands in skeletal muscle strength, regeneration, and pathology, from 2018-10-01 to 2023-03-31